Scarica l'app Stockscreener
10.55
5.89%
-0.66
Dbv Technologies Adr Borsa (DBVT) Ultime notizie
DBV Technologies Submits FDA Biologics License Application for VIASKIN Peanut Patch in Children Ages 4-7 - Kalkine Media
Citizens reiterates DBV Technologies stock rating on BLA milestone - Investing.com
DBV Technologies Announces Submission of Biologics License - GlobeNewswire
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years - GlobeNewswire Inc.
DBV Technologies S.A. (DBVT) Stock Price, News, Quote & History - Yahoo! Finance Canada
DBV technologies S.A. (ADR) (DBV1.SG) Q2 FY2026 earnings call transcript - Yahoo Finance
European ADRs Rose Late Thursday Morning, Led By Biotech - Finimize
DBVT Slides As DBV Technologies Leads Biotech ADR Losers - StocksToTrade
DBVT Slides As DBV Technologies Leads European Biotech Declines - timothysykes.com
DBV Technologies at Cantor conference: peanut allergy push advances By Investing.com - Investing.com UK
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Eastern Progress
Azitra Inc (AZTR) Peer Comparison – Compare with Others - Value Research
Zai Lab LimitedADR Peer Comparison – Compare with Others - Value Research
DBV Technologies S.A.ADR Key Financial Ratios – Valuation, Profitability & More - Value Research
DBV Technologies to Participate in Upcoming September Investor Conferences - GlobeNewswire
A food-allergy treatment company will join three New York events in September - Stock Titan
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
European ADRs Edged Higher As Biotech Led The Pack - Finimize
DBV Technologies (NASDAQ:DBVT) Shares Up 6.2%Here's Why - MarketBeat
European ADRs Started The Week Slightly Higher In US Trading - Finimize
MPM BioImpact LLC discloses 6.2% stake in DBV Technologies (DBVT) - Stock Titan
DBV technologies S.A. (ADR) (DBV1.SG) balance sheet - Yahoo Finance UK
DBV Technologies (NASDAQ:DBVT) Stock Price Up 8.4%Time to Buy? - MarketBeat
RA Capital discloses DBV Technologies (DBVT) 5.8% ownership via ADS holding - Stock Titan
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq - manilatimes.net
DBV Technologies Announces Sale of Approximately $50 - GlobeNewswire
Form S-3ASR DBV TECHNOLOGIES S.A. For: 27 July By Investing.com - Investing.com Canada
Spyre Therapeutics (SYRE) Receives a Buy from Guggenheim - The Globe and Mail
Europe’s US-Listed ADRs Edged Higher Late Friday Morning - Finimize
DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside (NASDAQ:DBVT) - Seeking Alpha
DBV Technologies on Track for Lowest Close Since December 2025 -- Data Talk - Moomoo
We Think DBV Technologies (EPA:DBV) Needs To Drive Business Growth Carefully - Simply Wall Street
DBV Technologies stock falls on $150M share offering plan - Investing.com
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales - The Manila Times
symbol__ Stock Quote Price and Forecast - CNN
Citizens reiterates Market Outperform on DBV Technologies stock, $55 target - Investing.com
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update - markets.businessinsider.com
DBV Technologies narrows Q2 loss, funds operations into Q3 2027 - scanx.trade
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report - markets.businessinsider.com
DBV Technologies (NASDAQ: DBVT) sees $174.9M cash and Q3 2027 runway - Stock Titan
DBV Technologies Announces the Filing of its 2026 Half-Year - GlobeNewswire
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 - markets.businessinsider.com
DBV Technologies' July 16 webcast will cover Q2 results - Stock Titan
ETFs Investing in DBV Technologies SA Sponsored ADR Stocks - TradingView
Europe’s US-Listed ADRs Slipped Late Tuesday Morning - Finimize
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - markets.businessinsider.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
DBV Technologies (NASDAQ: DBVT) targets Q3 2026 for VIASKIN Peanut BLA filing - Stock Titan
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing - The Manila Times
European ADRs Rose As Biopharma Names Led The Pack - Finimize
A40WEX Forecast — Price Target — Prediction for 2027 - TradingView
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):